Navigation Links
CitiusTech Completes Another Milestone Year: Revenues Grow by 59% in 2011
Date:2/15/2012

PRINCETON, New Jersey, February 15, 2012 /PRNewswire/ --

CitiusTech, a leading healthcare technology solution provider, announced that it has completed the calendar year 2011 with 59% growth in revenues. 2011 is now the fifth consecutive year that CitiusTech has recorded over 50% Y-o-Y revenue growth. In 2011, CitiusTech won the Red Herring Award for leadership in healthcare technology. CitiusTech was selected as a finalist at the 2011 American Business Awards for being one of the fastest growing technology companies in the United States.

Growth in 2011 has been driven by existing customer relationships (93% customer retention) and by new customer additions across North America and Europe.  CitiusTech also enhanced its capabilities across its key service offerings - software product engineering, professional services and healthcare BI/analytics. CitiusTech's BI-Clinical platform became the only modular BI solution to be ONC-ATCB 2011/2012 certified for all Eligible Hospital (EH) and Eligible Professional (EP) Meaningful Use Clinical Quality Measures. BI-Clinical was also one of the first BI/analytics platforms to comply with all 33 ACO quality measures that were released by CMS.

During 2011, CitiusTech's software engineering practice enabled many leading healthcare IT vendors to enhance and architect their solutions (e.g., for mobile and cloud computing) and comply with new technology and regulatory needs (including Meaningful Use, ACO etc.). In addition, CitiusTech professional services team formed strategic partnerships with HIE, EMR and clinical application organizations to help them scale their professional services organizations worldwide. With over 250 HL7 certified professionals, CitiusTech retains the distinction of having the largest number of certified interoperability professionals worldwide. CitiusTech also expanded its reach, with new offices in Princeton NJ, Singapore and India.

"2011 has been an excellent year for C
'/>"/>

SOURCE CitiusTech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
2. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
3. Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
4. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
5. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
6. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
7. China Sky One Medical, Inc. Completes Acquisition of Peng Lai Jin Chuang Company
8. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
9. Roche completes acquisition of ARIUS
10. Water Street Health Care Partners Completes Agreement With Gentiva Health Services to Acquire Majority Ownership of CareCentrix
11. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... in German . ... dots in a semiconductor layer. Quantum dots are small structures ... If a short laser pulse is fired at the photonic ... experiences a change in the electromagnetic field around it. This ... light by the dot. As soon as the refractive index ...
(Date:9/30/2014)... Using a bio-mimicking analog of one of nature,s ... international research team led by Alejandro Briseno of ... major step in developing long-sought polymer architecture to ... use in electronic devices. , Briseno, with ... others at Stanford University and Dresden University of ...
(Date:9/30/2014)... 30, 2014 Shimadzu Scientific Instruments ... easy-to-use and highly precise tool for measuring displacement ... elongation. With 1000-mm maximum movement distance, the DSES-1000 ... a gauge length of 10 mm. In addition, ... above 50-mm stroke and within +/- 100 µm ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Proove ... medicine, is excited to announce a new genetic test ... The Proove Pain Perception Test will provide physicians ... and why pain tolerance levels are stratified between individuals. ... identify whether a person has a genetic predisposition that ...
Breaking Biology Technology:Ultrafast remote switching of light emission 2Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3
... - YM BioSciences Inc. (NYSE Amex: YMI ... company that identifies and advances a diverse portfolio ... development, today reported that its licensee for nimotuzumab, ... has commenced enrollment of a Phase II trial ...
... and to Complete Current Phase 3 Trial of Naturlose(R) ... June 23 Spherix Incorporated (Nasdaq: SPEX ... a provider of technical and regulatory consulting services to ... it has received its first full-scale production batch of ...
... Medical Device & Diagnostic Industry Magazine,s 30 Years, 30 Devices Special ... 23 Medical Device and Diagnostic Industry has recognized ... a leader in infusion therapy and pain management as well as ... as being among the most influential medical devices of the last ...
Cached Biology Technology:YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB 2YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB 3YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB 4YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB 5Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 2Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 3Spherix Announces Full-Scale Production of Pharmaceutical Tagatose 4B. Braun Medical Inc. Recognized by Industry for Manufacturing Influential Medical Devices 2B. Braun Medical Inc. Recognized by Industry for Manufacturing Influential Medical Devices 3B. Braun Medical Inc. Recognized by Industry for Manufacturing Influential Medical Devices 4
(Date:9/29/2014)... Washington, DC Monday, September 29: Between 1970 ... and fish around the globe dropped 52 percent, ... by World Wildlife Fund (WWF). This biodiversity loss ... increasing resource use of high-income countries. , In ... the report,s data point to other warning signs ...
(Date:9/29/2014)... school? According to a new Food and Brand Lab ... can increase participation in the National School Lunch Program ... vegetables by 16%! , Chefs Move to Schools (CMTS), ... chefs with schools in order to provide nutrition instruction ... service workers. , A CMTS event was held in ...
(Date:9/29/2014)... team says recently identified radiation detection properties of a ... for homeland security and medical advances. , In a ... of Optics Letters , UT Arlington Physics Professor ... to fabricate transparent nanoscintillators by heating nanoparticles composed of ... formed. A scintillator refers to a material that ...
Breaking Biology News(10 mins):Half of global wildlife lost, says new WWF report 2Chefs move to schools can increase school meal participation and vegetable intake among students 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 2UT Arlington researchers develop new transparent nanoscintillators for radiation detection 3
... y MUNICH, 7 de noviembre de 2012 Bausch + ... ejercitación de su opción de compra de todas las acciones ... Vision GmbH (TPV), una destacada compañía láser de oftalmología. ... de una sociedad mixta entre Bausch + Lomb y 20/10 ...
... 2012 Bausch + Lomb, a empresa global de saúde ... as ações em circulação e sem controle da Technolas ... A Technolas Perfect Vision foi criada em 2009 ... + Lomb e a 20/10 PERFECT VISION AG para desenvolver ...
... well known for attacking a protein associated with the ... it also degraded a different protein that triggers blood ... a key challenge in the battle against cancer, according ... in the University of Leeds, Faculty of Biological Sciences., ...
Cached Biology News:Bausch + Lomb adquiere Technolas Perfect Vision GmbH 2Bausch + Lomb adquiere Technolas Perfect Vision GmbH 3Bausch + Lomb adquiere Technolas Perfect Vision GmbH 4Bausch + Lomb prestes a adquirir a Technolas Perfect Vision GmbH 2Bausch + Lomb prestes a adquirir a Technolas Perfect Vision GmbH 3Bausch + Lomb prestes a adquirir a Technolas Perfect Vision GmbH 4Breast cancer drug could halt other tumors 2
Rabbit polyclonal to hnRNP-U...
... iTaq DNA polymerase is ... suitable for both conventional and ... is supplied at a concentration ... and includes 250 units polymerase, ...
... (E.C. 3.1.21.1) is a nonspecific endonuclease that ... functions by hydrolyzing phosphodiester linkages, producing mono ... 3'-hydroxyl group. Ambion's RNase-free DNase I is ... recommended to degrade DNA in the presence ...
RABBIT ANTI RHEB (IN) Immunogen: A 15 amino acid peptide located in the central region of human Rheb....
Biology Products: